The european medicines Agency (EMA) has recommended on Thursday the approval of "placing on the market conditional" of the antiviral remdesivir within the european Union for patients with the new coronavirus. "The remdesivir is the first drug against the Covid-19 to be recommended for authorisation in the EU ", said in a statement that the agency based in The Hague, adding that this recommendation must now be approved or not by the european Commission.
also Read "From Sars, we would have had to have medication ready on the shelves"
also Read Vaccines Covid-19 : "You must not sell the skin of the bear before having killed him"
Developed in the fight against Ebola
A study of the EMA has shown that patients with Covid-19 and treated with remdesivir is recovering, on average, four days faster than other patients. Originally developed against the Ebola hemorrhagic fever, the remdesivir of the american laboratory Gilead is the first therapy to have shown a certain efficacy in patients hospitalized for Covid-19 in a clinical trial of significant size, even if the effect is considered modest. The use in emergency remdesivir in hospitals has been authorized by the United States, and then by Japan.